Biogen Reports Ten-Year AFFIRM Data for Tysabri in Relapsing Multiple Sclerosis

Biogen today presented ten-year follow-up data from the AFFIRM trial evaluating Tysabri (natalizumab) in patients with relapsing multiple sclerosis. The data showed that patients who received Tysabri maintained significant reductions in annualized relapse rates and disability progression over ten years. The long-term safety profile was consistent with previous observations.